Cas:154701-59-4 (s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole manufacturer & supplier

We serve Chemical Name:(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole CAS:154701-59-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole

Chemical Name:(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole
CAS.NO:154701-59-4
Synonyms:(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole
Molecular Formula:C10H10BrNO
Molecular Weight:240.09600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:21.59000
Exact Mass:238.99500
LogP:2.05000

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole Use and application,(s)-2-(2-bromophenyl)-4-methyl-4,5-dihydrooxazole technical grade,usp/ep/jp grade.


Related News: “We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.” 5,5′-dimethoxy-[1,1′-biphenyl]-2,2′-dicarbaldehyde manufacturers With its offering of API development, GMP manufacturing, solid state chemistry and analytical expertise, Onyx continues to experience strong growth driven by demand from biotech and pharmaceutical companies for its integrated CMC capabilities. 1,6-Hexanediamine, N-[(3b)-cholest-5-en-3-yl]- suppliers Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. 1-(4-chlorophenyl)sulfanylpropan-2-amine,hydrochloride vendor & factory.